Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

While some GLP-1s are approved for patients age 12 and older, only a few telehealth companies will prescribe them to children.

Danish pharmaceutical giant Novo Nordisk sees a significant increase in profits and sales despite production constraints.

Current health news highlights the expected high demand for Novo Nordisk's obesity drug in India, the need for personalized approaches in knee replacement surgeries, Gilead's notable financial ...

4️⃣ Drug warning: Compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, have been associated with ...

Health-care companies ticked up amid mixed earnings and consolidation prospects. ADRs of Danish drug giant Novo Nordisk fell after sales of its blockbuster Wegovy weight-loss drug failed to surpass ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk's Wegovy sales exceed forecasts, boosting shares by 9%. U.S. demand remains high with expanded supply plans and ...